• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
Menu
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Synairgen announces positive Phase 2 results for inhaled interferon beta

UK-based Synairgen has announced positive data from a Phase 2 trial of its SNG001 inhaled interferon beta as protection against the common cold and other respiratory viral infections in asthma patients. According to the company, SNG001 showed statistically significant improvements compared to placebo in prevention of symptom worsening during the first week of infection, in the percentage of patients experiencing exacerbations, and in the reduction of the use of reliever inhalers on days 5 and 6.

In addition, the patients who received SNG001 experienced a steady increase in morning peak expiratory flow compared as opposed to those receiving placebo who experienced an initial reduction prior to improvement. The study included 134 adult patients with mild-to-moderate or severe asthma who were suffering from cold symptoms.

Development of SNG001 was initially funded by the Medical Research Council, Asthma UK, the British Lung Foundation, the National Institute of Health Research, and the University of Southampton. Synairgen licensed the intellectual property from the University of Southampton; the US granted a patent in 2009, and a European patent was granted in 2010.

Synairgen co-founder Stephen Holgate said, “This is a really promising breakthrough for the future treatment of asthma and one of the most exciting developments that I have seen in years. This is the first clinical study which appears to demonstrate that, by boosting the antiviral defences of the lungs of asthmatics rather than trying to inhibit rapidly evolving viruses, we can limit the adverse effects of viral infection significantly to prevent worsening of asthma symptoms in a high risk group of patients.”

Asthma UK Assistant Director of Research Leanne Metcalf added, “This has the potential to be one of the biggest breakthroughs in asthma treatments in the past 20 years. We are incredibly excited by the possibilities this research could bring to reduce hospital admissions and deaths as a result of asthma attacks. Over 80% of asthma attacks are triggered by cold and flu viruses, and until now we haven’t had any effective treatments that can stop this from happening. This clinical trial demonstrates the potential of this anti-viral drug to prevent asthma attacks for thousands of people with severe asthma. We are incredibly proud to have played a part in the realisation of this research programme which should benefit people with asthma in a really significant way.”

Read the Synairgen press release.

Share

published on April 19, 2012

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews